Breast Cancer – TheNewsHub https://thenewshub.in Fri, 18 Oct 2024 16:06:02 +0000 en-US hourly 1 https://wordpress.org/?v=6.7 Op-ed: The financial toxicity of cancer is growing. Here's what can be done to reduce it https://thenewshub.in/2024/10/18/op-ed-the-financial-toxicity-of-cancer-is-growing-heres-what-can-be-done-to-reduce-it/ https://thenewshub.in/2024/10/18/op-ed-the-financial-toxicity-of-cancer-is-growing-heres-what-can-be-done-to-reduce-it/?noamp=mobile#respond Fri, 18 Oct 2024 16:06:02 +0000 https://thenewshub.in/2024/10/18/op-ed-the-financial-toxicity-of-cancer-is-growing-heres-what-can-be-done-to-reduce-it/

Medical personnel use a mammogram to examine a woman’s breast for breast cancer.

Hannibal Hanschke | dpa | Picture Alliance | Getty Images

Cancer drains individuals of their physical, emotional, and financial health. Given the impact on both patients and the people in their lives — including their employer — it’s time that CEOs take note and take action to reduce the burden of cancer.

In a study from the American Cancer Society Cancer Action Network, nearly half of cancer patients and survivors reported being extraordinarily burdened by medical debt. Many respondents carried a negative balance of at least $5,000 from their cancer treatment for more than one year, and 42% of people with cancer deplete their life savings within the first two years after diagnosis.

Financial hardship caused by cancer can also contribute to “financial toxicity,” wherein the cost of treatment forces individuals to make tradeoffs that impact their chances of survival. These may include non-biologic factors such as skipping or halving cancer medications to stretch their supply, or being unable to complete cancer care as planned due to the high costs of transportation to or housing near cancer treatment centers. This model isn’t sustainable, and rising costs of new, life-saving cancer therapies will impose additional financial toxicities — and an increasingly large threat to patients’ lives.

Not only does financial toxicity of cancer care affect the individual, it can also negatively impact their employer. As the providers of health insurance coverage for nearly half the country, employers and unions shoulder much of cancer’s financial burden. Today, cancer is the leading health-care cost for mid- and large-sized organizations in the U.S., and the burden is growing.

For the first time in history, more than 2 million Americans will receive a new cancer diagnosis in 2024. While increasing cancer incidence can be attributed in part to our aging population (cancer risk increases with age), we also see a disturbing national trend in which younger people are being diagnosed with 17 major cancers. These are people who would still likely be in the workforce, using employer-sponsored health insurance. As a result, employers are asking what they can do to reduce the burden of cancer on their populations — and their bottom line.

Patients, families, and employers all “win” when cancers are diagnosed at an early stage. Detecting cancer early not only improves chances of survival, it significantly lowers the cost of care. Overall, treatment costs for someone diagnosed at stage IV — when cancer has spread throughout the body — are an average of $156,000 higher than for those diagnosed at stage I, when the disease is localized. The first year of treatment for colorectal cancer, which affects over 150,000 individuals each year in the United States and is on the rise in younger populations, costs an average of $111,000 when diagnosed at stage I, with about a 90% five-year survival rate. By contrast, stage IV colorectal cancer drives average treatment costs of $256,000 in the first year, and five-year survival rates are under 20%. Evidence suggests that if individuals could only take advantage of the prevention, early detection, and cancer treatment strategies that exist today, the cancer mortality rate would decline by 30% to 50%.

These statistics are profound and strongly suggest that concerted efforts from employers and individuals to encourage cancer prevention and early detection would improve health and reduce health-care costs. Today, our best tool to achieve this is screening. Adherence to recommended screening guidelines — like those published by ACS — could save the U.S. health-care system $26 billion per year in avoided treatment costs.

Despite the importance of early detection and proven value of screening, access to preventive care remains a barrier to better outcomes. At present, a staggering 65% of eligible Americans are out-of-date with recommended cancer screenings. Covid-19 restrictions delayed or prevented 9.4 million cancer screenings in 2020 alone, likely leading to later-stage diagnoses that would have normally been caught earlier.

There are also logistical and societal barriers that contribute to financial toxicities and impact a person’s ability to get screened. People may need to take time off work or arrange childcare to attend a screening appointment. They may need to weigh potential future treatment costs against their need to pay rent. Some may not be aware they’re eligible for screening, and stigma and fear associated with cancer screening hinders some people from seeking care. Inequities according to one’s socioeconomic status — including where they live, their income, education level, access to healthcare and healthy foods, and other social determinants of health — create roadblocks to preventive care. To realize the benefits of early detection on individuals and organizations, it’s important that we develop new strategies to remove these barriers.

American Cancer Society CEO Karen Knudsen

NYSE

ACS is committed to tackling cancer, approaching the challenge of improving access to care and reducing financial toxicity from multiple angles. Similar or supportive action from U.S. employers will increase our collective impact against cancer’s burden.

Toward the goal of increasing early detection, ACS recently partnered with Color Health in a joint venture to improve access to screening and preventive care through employers and unions. By making it easier and more convenient for employees to get care — with at-home testing kits and care navigation support across their cancer journey — this program aims to increase awareness, accessibility, and affordability of cancer screening and early detection. Notably, organizations taking advantage of the ACS-Color program have witnessed a 77% increase in cancer screening adherence.

In addition to direct screening initiatives, programs like Road to Recovery and ACS Hope Lodges remove the cost burdens of transportation and lodging for cancer treatment. Other partnerships through BrightEdge, ACS’s donor-funded innovation and investment arm, provide access to a wide range of solutions that help people navigate the financial complexities of cancer across the continuum of care. One BrightEdge portfolio company, TailorMed, offers a platform to help patients find resources to cover the cost of treatment and reduce out-of-pocket expenses. Further investments aim to bring the patient voice into therapy and diagnostic development, to enable a future generation of sustainable cancer innovations that reduce patients’ financial distress.

Advocacy is also key to reducing financial toxicity. ACS’s Cancer Action Network advocates for Medicaid expansion to help currently uninsured individuals access screening and preventive care. To bring down the cost of prescription drugs, ACS CAN has also successfully advocated for “smoothing,” a policy that allows Medicare beneficiaries to spread out their prescription drug costs over the course of the year. By making payments more manageable for patients, we remove a crucial element of the cancer financial challenge.

Cancer will impact one in two women and one in three men at some point in their lifetime. By facilitating guideline-recommended screening and activating programs that make early detection affordable and accessible, employers can offset financial toxicities and improve outcomes for people across the country. When employers help their employees get screened, they bring us one step closer to ending cancer — and its costs — as we know it.

By Karen Knudsen, CEO of the American Cancer Society. She is also a member of the CNBC CEO Council.

]]>
https://thenewshub.in/2024/10/18/op-ed-the-financial-toxicity-of-cancer-is-growing-heres-what-can-be-done-to-reduce-it/feed/ 0
Breast Cancer Awareness Month: The Evolution of Combination Therapies in Breast Cancer Treatment https://thenewshub.in/2024/10/16/breast-cancer-awareness-month-the-evolution-of-combination-therapies-in-breast-cancer-treatment/ https://thenewshub.in/2024/10/16/breast-cancer-awareness-month-the-evolution-of-combination-therapies-in-breast-cancer-treatment/?noamp=mobile#respond Wed, 16 Oct 2024 15:41:48 +0000 https://thenewshub.in/2024/10/16/breast-cancer-awareness-month-the-evolution-of-combination-therapies-in-breast-cancer-treatment/

According to the American Cancer Society, breast cancers in the early stage have a survival rate of 99% compared to later-stage cancers at 24%. (Representative Image)

Breast cancer treatment therapies, which combine multiple drugs, not only improve treatment outcomes but also increase patient convenience, reducing the burden of treatment.

Breast cancer treatment has undergone significant advancements over the years, with combination therapies emerging as a pivotal strategy in enhancing care. These therapies, which combine multiple drugs, not only improve treatment outcomes but also increase patient convenience, reducing the burden of treatment.

Dr. Meenu Walia, Vice Chairman of the Department of Medical Oncology and Hematology, Max Super Specialty Hospital, highlights how the evolution of combination therapies is transforming breast cancer care:

“Breast cancer treatment has come a long way, and the evolution of combination therapies is a game-changer in how we approach care. The introduction of newer drugs not only enhances treatment effectiveness but also significantly improves patient convenience. With innovations like the world’s first fixed-dose combination of Pertuzumab and Trastuzumab, patients with HER-2 positive breast cancer can now receive treatment subcutaneously in just a few minutes, instead of hours, thereby reducing chair time by up to 90%.”

This advancement means patients spend significantly less time in clinics and more time living their lives, focusing on their well-being without the constant reminder of their condition.

Dr. Chirag Desai, Director of Medical Oncology at HOC Vedant in Ahmedabad, echoes the importance of targeted treatments and fixed-dose combinations (FDCs) in improving the breast cancer treatment landscape.

“Innovative therapies, especially targeted treatments like FDCs, are transforming the treatment landscape. These therapies are not only more effective but also offer greater convenience with subcutaneous administration. By eliminating the need for cannula insertion, they allow patients to focus on their well-being without the constant reminder of their disease.”

Beyond patient comfort and convenience, these combination therapies offer broader benefits to healthcare systems. Dr. Desai emphasizes, “These treatments optimize hospital resources by reducing staff requirements and preparation times, enhancing both treatment efficiency and overall workflow.”

The combination of Pertuzumab and Trastuzumab, specifically for patients with HER-2 positive breast cancer, is a prime example of how innovation in treatment delivery can enhance both clinical outcomes and patient experience. This fixed-dose combination not only improves the efficacy of cancer therapy but also lessens the physical and emotional toll on patients by making the treatment process quicker and less invasive.

As these advanced therapies continue to evolve, they signify a shift toward more patient-centered care, offering breast cancer patients not just more effective treatments, but also a better quality of life.

]]>
https://thenewshub.in/2024/10/16/breast-cancer-awareness-month-the-evolution-of-combination-therapies-in-breast-cancer-treatment/feed/ 0
Expert Debunks Common Breast Cancer Myths: Separating Fact From Fiction https://thenewshub.in/2024/10/11/expert-debunks-common-breast-cancer-myths-separating-fact-from-fiction/ https://thenewshub.in/2024/10/11/expert-debunks-common-breast-cancer-myths-separating-fact-from-fiction/?noamp=mobile#respond Fri, 11 Oct 2024 12:22:00 +0000 https://thenewshub.in/2024/10/11/expert-debunks-common-breast-cancer-myths-separating-fact-from-fiction/

Thanks to extensive medical research, we now understand more about breast cancer’s biology and treatment than ever before. Public awareness campaigns have helped educate people about breast cancer, which affects one in six women in India. However, many myths about breast cancer continue to circulate online and even among well-meaning individuals.  

Dr. Sachin Ambekar, Director of Minimal Access Surgery, Surgical Oncology & Medical Director at MASSH Hospital has debunked common breast cancer myths: 

Myth 1: Most women diagnosed with breast cancer have a family history or genetic mutation.   

Fact: Only 10-15% of breast cancers are caused by inherited genetic mutations such as BRCA1, BRCA2, and PALB2. While these mutations do increase the risk, the majority of women diagnosed with breast cancer have no known genetic mutations or family history. 

Myth 2: Only women can get breast cancer.   

Fact:  Although breast cancer is predominantly diagnosed in women, men can develop it too. In 2023, around 2,790 men were diagnosed with breast cancer. Male breast cancer is often undertreated, which leads to worse outcomes. Men also have breast tissue, making them susceptible to the disease. 

Myth 3: Only older people are diagnosed with breast cancer.   

Fact:  While breast cancer is more common in women over 50, younger women are increasingly being diagnosed. Over the past five years, diagnoses in women under 50 have risen by more than 2% annually. These younger women often face more aggressive forms of the disease and are diagnosed at later stages, leading to worse outcomes. 

Myth 4: You can’t reduce your risk of breast cancer.   

Fact:  While there’s no guaranteed way to prevent breast cancer, women can take proactive steps to protect their breast health: 

– Undergo a breast cancer risk assessment. 

– Learn your family history of cancer. 

– Understand the normal appearance of your breasts. 

– Eat a healthy diet, limit alcohol, quit smoking, and exercise regularly. 

Myth 5: Mammograms aren’t effective.   

Fact: Mammograms have saved millions of lives by detecting breast cancer early. Early detection increases the likelihood of successful treatment with less invasive options. New technologies like contrast-enhanced spectral mammography and AI-powered thermal imaging further enhance screening capabilities. 

Myth 6: Everyone’s breast cancer is the same.   

Fact: Breast cancer is not a single disease but a collection of diseases with different drivers, prognoses, and treatment responses. Research continues to personalize breast cancer treatment, matching therapies to individual tumor characteristics for better outcomes. 

Myth 7: Breast cancer always presents as a lump.   

Fact: While lumps are a common sign, breast cancer can also manifest as breast swelling, skin dimpling, nipple discharge, or a red rash. Many women are diagnosed during routine screenings before symptoms appear. 

Myth 8: Wearing wire bras or using antiperspirants increases breast cancer risk.   

Fact: Studies have debunked these claims. A 2014 study of 1,500 women found no association between bra-wearing habits and breast cancer risk. Additionally, there is no scientific evidence linking antiperspirant deodorants to breast cancer development. 

Myth 9: Eating sugar causes breast cancer to grow faster.  

Fact: No research shows that cutting out sugar shrinks cancer. However, a diet high in refined sugar can lead to obesity and inflammation, which are risk factors for breast cancer. A balanced diet that limits processed sugars is recommended. 

By debunking these myths, we hope to better educate the public and promote proactive breast health. 

]]>
https://thenewshub.in/2024/10/11/expert-debunks-common-breast-cancer-myths-separating-fact-from-fiction/feed/ 0
Neighbors bond over breast cancer journeys as rates rise among AAPI women https://thenewshub.in/2024/10/09/neighbors-bond-over-breast-cancer-journeys-as-rates-rise-among-aapi-women/ https://thenewshub.in/2024/10/09/neighbors-bond-over-breast-cancer-journeys-as-rates-rise-among-aapi-women/?noamp=mobile#respond Wed, 09 Oct 2024 02:05:00 +0000 https://thenewshub.in/2024/10/09/neighbors-bond-over-breast-cancer-journeys-as-rates-rise-among-aapi-women/

PLYMOUTH, Minn. — New data shows the breast cancer rate is growing each year in women under 50, with the highest increase in Asian American and Pacific Islander women.

Plymouth residents Sara Pelissero and Jackie Bohline call each other the “doppelneighbors.”

“We live next door, we’re both adopted from Korea, we both married White men, we both have small white dogs,” Pelissero said.

But life got serious after Pelissero moved in. Right after having her baby girl, she felt a lump.

“I was diagnosed at 33. I was still years away from having my first mammogram. But it was a sense of like something’s not right and something’s off,” Pelissero said.

After surgery and treatment, the cancer left her body. But then a few years later, a call brought it all back.

“I was like, ‘I just need to hug you,’ and like we both cried together, and it was just a situation, you don’t want anybody to be part of this club,” Pelissero said.   

Sara Pelissero and Jackie Bohline

WCCO


Bohline had cancer, too. She found out after having her very first mammogram at 40. It was an aggressive cancer. Had she waited longer, it would have advanced.

“You want to catch it as early as you can because that’s when these treatments become powerful,” Bohline said.

Bohline says she wants others to know that age doesn’t matter when it comes to breast cancer.

“It’s everywhere, unfortunately. It’s one in eight women, and so that’s a high statistic,” Bohline said.

“You know yourself better than anyone, you know when something’s not right. Don’t ignore that feeling,” Pelissero said.

The proud moms now share something else: they’re both finally cancer-free.

“We will be together forever (laughs)!” Bohline said.

Bohline says from her recent journey, she has three big takeaways for anyone facing a new diagnosis:

  • Get mammograms every year right on the dot
  • Be bold in advocating for yourself and make sure you choose doctors you’re fully comfortable with and trust
  • Get genetic testing so you can fully understand your family history

]]>
https://thenewshub.in/2024/10/09/neighbors-bond-over-breast-cancer-journeys-as-rates-rise-among-aapi-women/feed/ 0
"The Office" star Jenna Fischer reveals breast cancer diagnosis, treatment https://thenewshub.in/2024/10/08/the-office-star-jenna-fischer-reveals-breast-cancer-diagnosis-treatment/ https://thenewshub.in/2024/10/08/the-office-star-jenna-fischer-reveals-breast-cancer-diagnosis-treatment/?noamp=mobile#respond Tue, 08 Oct 2024 22:29:00 +0000 https://thenewshub.in/2024/10/08/the-office-star-jenna-fischer-reveals-breast-cancer-diagnosis-treatment/

Actress Jenna Fischer, known for her role as Pam Beesly in the sitcom “The Office,” revealed that she was diagnosed with breast cancer last year but is now cancer-free after receiving treatment.

Fischer said in a post on Instagram on Tuesday she was diagnosed with Stage 1 triple-positive breast cancer in December of last year after an inconclusive mammogram led to a breast ultrasound. 

“I never thought I’d be making an announcement like this but here we are. Last December, I was diagnosed with Stage 1 Triple Positive Breast Cancer. After completing surgery, chemotherapy and radiation I am now cancer-free,” Fischer wrote. 

The Instagram post included a series of slides detailing her cancer diagnosis and treatment. She also urged her followers to schedule their annual mammograms. 

Fischer wrote that triple-positive breast cancer is an aggressive form of cancer but is highly responsive to treatment. She said she underwent a lumpectomy to remove a tumor in January, followed by 12 rounds of weekly chemotherapy and weeks of radiation. “Luckily my cancer was caught early and it hadn’t spread to my lymph nodes or throughout the rest of my body,” she wrote. 

“I’m happy to say I’m feeling great,” Fischer added.

Fischer also revealed she had lost her hair during the chemotherapy and had been wearing wigs.

“I’m making this announcement for a few reasons. One, I’m ready to ditch the wigs. Two, to implore you to get your annual mammograms,” she wrote.

“I’m serious, call your doctor right now,” she added. “My tumor was so small it could not be felt on a physical exam. If I had waited six months longer, things could have been much worse. It could have spread.”

In the post she also thanked her medical team, husband, family and friends. “It takes a village to fight cancer, and I have had an amazing village,” Fischer, a mother of two children, 10 and 13, wrote. 

She also thanked her best friend and “The Office” co-star Angela Kinsey, “who protected and advocated for me.”

Fischer and Kinsey host a podcast, “Office Ladies,” where they discuss episodes of “The Office” and share behind-the-scenes stories about the sitcom.

“For a long time, she was the only person in my workspace who knew,” Fischer wrote. “When I lost my hair, she wore hats to our work meetings so I wouldn’t be the only one. When I needed a break, we took one. I am so lucky to have a career with this kind of flexibility. Cancer treatment requires a lot of flexibility. For a gal who likes to plan, that was a hard adjustment. But, continuing to work has brought so much joy to my life during treatment.”



]]>
https://thenewshub.in/2024/10/08/the-office-star-jenna-fischer-reveals-breast-cancer-diagnosis-treatment/feed/ 0